Reshape Lifesciences (NASDAQ:RSLS) just reported results for the first quarter of 2024.
- Reshape Lifesciences reported earnings per share of -9 cents. This was above the analyst estimate for EPS of -16 cents.
- The company reported revenue of $1.94 million.
- This was 7.43% worse than the analyst estimate for revenue of $2.10 million.